Instil Bio, Inc.

TIL Healthcare Biotechnology

In the quarter to June 2026, EPS grew 80.6%, free cash flow grew 68.6% and total debt was flat, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

5.91 0.22 −3.59%
Market cap
$41.6M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(25.33%) (37.07%) (50.39%) (50.60%)

+8 more TTM periods

ROA
(14.13%) (21.64%) (30.56%) (31.00%)
ROIC
(18.94%) (28.42%) (40.13%) (40.39%)
Return on Tangible Assets
(16.82%) (25.79%) (38.23%) (39.37%)
Average Days of Receivables
— — — —
Free Cash Flow per Share
(3.48) (4.98) (5.49) (5.93)
Free Cash Flow
(23.61) (33.76) (36.62) (40.10)
Other line items
Cash ROIC
(8.99%) (12.49%) (13.32%) (14.07%)
Accounts Payable Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
0.00 0.00 0.00 0.00
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Interest Coverage
(5.92) (8.76) (13.48) (11.12)
Operating CF/Net income
0.78 0.71 0.51 0.53
Depreciation/Fixed assets
0.00 0.43 4.24 9.15
Capex/Depreciation
0.00 0.00 0.00 0.00
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(3.48) (4.98) (5.49) (5.93)
Capex per Share
0.00 0.00 0.00 0.00

Fold the line items

Columns are period end dates